Document text
Principal Investigator: PERRY E BICKEL
Organization: UT SOUTHWESTERN MEDICAL CENTER
Fiscal Year: 2024
Award: $519,551
Funding agency: National Institute of Diabetes and Digestive and Kidney Diseases
Project Abstract/Summary
The rising prevalence of obesity and type 2 diabetes threatens to limit human healthspan by increasing the
risks for cancer and cardiometabolic disease and to impose overwhelming economic burdens. New
therapeutic strategies are urgently needed. Since the discovery of functional brown and beige adipocytes in
adult humans, much attention has focused on exploiting the ability of these thermogenic adipocytes to
dissipate excess energy as heat through uncoupled mitochondrial respiration. Advanced imaging in humans
has revealed a favorable correlation between brown fat mass and cardiometabolic risk factors. A major gap
in the field is a safe and effective pharmacological strategy to activate brown and/or beige adipocytes to
promote negative energy balance, reverse obesity, and mitigate obesity-related metabolic disorders, such
type 2 diabetes, cardiovascular disease, and nonalcoholic fatty liver disease. The overall goal of this
application is to provide proof-of-concept for one such strategy that has been suggested by the lab’s long-
standing research program on Perilipin 5 (PLIN5), a member of the Perilipin family of lipid droplet proteins
that is expressed in oxidative tissues, including brown adipose tissue (BAT). A growing body of literature
from our lab and others has implicated PLIN5 not only in the regulation of lipolysis at the lipid droplet
surface, but also in the regulation of gene expression via interactions in the nucleus with SIRT1 and PGC1a
and in the tethering of lipid droplets to mitochondria. Our published work in mice has shown that PLIN5 is
required for the metabolic, transcriptional, and mitochondrial adaptations of BAT to cold stress. We have
also shown that PLIN5 gain-of-function in BAT of mice can prevent glucose intolerance and fatty liver from
high-fat diet and promote healthy remodeling of white adipose tissue (WAT) with prevention of adipocyte
hypertrophy. In this renewal application we propose to test the hypothesis that promoting PLIN5 expression
in BAT in conjunction with b3 adrenergic receptor agonist treatment of diet-induced obese mice will reverse
adipocyte hypertrophy in WAT, reverse obesity, and reverse glucose intolerance. Aim 1 will elucidate the
metabolic and signaling pathways responsible for the effects of PLIN5 on mitochondrial form and function in
BAT and on systemic lipid and glucose metabolism by means of genetic mouse models, in vivo structure-
function studies, and mechanistic mitochondrial experiments. Aim 2 will interrogate the signaling pathways
and physiological responses associated with treatment of diet-induced obesity with a 2-hit intervention built
on augmentation of PLIN5 in BAT in synergistic combination with b3 adrenergic receptor agonist treatment.
Successful completion of these Aims may establish the conceptual foundation for a new therapeutic
paradigm for treatment of obesity that is efficacious but at lower, non-toxic doses of existing medications.
Terms: <21+ years old><Adenosine Cyclic Monophosphate-Dependent Protein Kinases><Adipocytes><Adipose Cell><Adipose tissue><Adrenergic Agonists><Adrenergic Receptor Agonist><Adrenomimetics><Adult><Adult Human><Adult-Onset Diabetes Mellitus><Affect><Agonist><Alleles><Allelomorphs><Ampullary Crest><Attention><Biogenesis><Blood Glucose><Blood Sugar><Body Tissues><Body Weight Changes><Body Weight decreased><Brown Adipose Tissue><Brown Fat><Cardiometabolic Disease><Cardiometabolic Disorder><Cardiovascular Diseases><Catecholamines><Cell Communication and Signaling><Cell Nucleus><Cell Signaling><Cell Size><Crista ampullaris><Cyclic AMP-Dependent Protein Kinases><Diabetes Mellitus><Distal><Dose><Doxycycline><Drugs><Economic Burden><Energy Expenditure><Energy Metabolism><Event><Family><Fat Cells><Fats><Fatty Acids><Fatty Liver><Fatty Tissue><Fatty acid glycerol esters><Foundations><Funding><Gene Action Regulation><Gene Expression><Gene Expression Regulation><Gene Regulation><Gene Regulation Process><Gene Transcription><Genes><Genetic><Genetic Transcription><Glucose Intolerance><Goals><Health><Heat Production><Hibernating Gland><High Fat Diet><Histology><Human><Humulin R><Hypertrophy><Image><Insulin><Intervention><Intervention Strategies><Intracellular Communication and Signaling><Ketosis-Resistant Diabetes Mellitus><Knock-out><Knockout><Knowledge><Lipids><Lipocytes><Lipolysis><Literature><Liver><Liver Steatosis><LoxP-flanked allele><Mature Lipocyte><Mature fat cell><Maturity-Onset Diabetes Mellitus><Mediating><Medication><Metabolic><Metabolic Diseases><Metabolic Disorder><Metabolic Pathway><Mice><Mice Mammals><Mitochondria><Modeling><Modern Man><Mouse Strains><Murine><Mus><NAFLD><NIDDM><Non obese><Non-Insulin Dependent Diabetes><Non-Insulin-Dependent Diabetes Mellitus><Noninsulin Dependent Diabetes><Noninsulin Dependent Diabetes Mellitus><Nonobese><Novolin R><Nuclear><Nucleus><Obese Mice><Obesity><Origin of Life><Outer Mitochondrial Membrane><PKA><Pharmaceutical Preparations><Phosphorylation><Physiologic><Physiological><Prevalence><Prevention><Protein Kinase A><Protein Phosphorylation><Proteins><Publishing><Pyruvate><RNA Expression><Regular Insulin><Regulation><Research><Respiration><Risk Factors><Role><SIRT1><SIRT1 gene><Signal Pathway><Signal Transduction><Signal Transduction Systems><Signaling><Sirtuin 1><Slow-Onset Diabetes Mellitus><Stable Diabetes Mellitus><Structure><Surface><Sympathins><T2 DM><T2D><T2DM><Testing><Therapeutic><Thermogenesis><Thesaurismosis><Tissues><Transcription><Type 2 Diabetes Mellitus><Type 2 diabetes><Type II Diabetes Mellitus><Type II diabetes><Vibramycin><Weight><Weight Change><Weight Loss><Weight Reduction><Weight maintenance regimen><Work><adipose><adiposity><adult onset diabetes><adulthood><alpha-6-Deoxyoxytetracycline><biological signal transduction><body weight loss><cAMP-Dependent Protein Kinases><cancer risk><cardiometabolic><cardiometabolic risk><cardiometabolism><cardiovascular disorder><cold stress><corpulence><crista ampulla><cristae><diabetes><diet-associated obesity><diet-induced obesity><diet-related obesity><drug/agent><energy balance><experiment><experimental research><experimental study><experiments><fat burning><fat metabolism><feeding><floxed><floxed allele><gain of function><glucose metabolism><glucose tolerance><health-span><healthspan><healthy life span><hepatic body system><hepatic organ system><hepatic steatosis><hepatosteatosis><imaging><improved><in vivo><inflammation marker><inflammatory marker><insight><insulin sensitivity><interventional strategy><ketosis resistant diabetes><lipid metabolism><loss of function><maturity onset diabetes><member><metabolism disorder><mitochondrial><mouse model><murine model><mutant><new approaches><new drug treatments><new drugs><new pharmacological therapeutic><new therapeutic approach><new therapeutic intervention><new therapeutic strategies><new therapeutics><new therapy><new therapy approaches><new treatment approach><new treatment strategy><next generation therapeutics><non-alcohol fatty liver disease><non-alcoholic fatty liver disease><non-alcoholic liver disease><nonalcoholic fatty liver disease><novel approaches><novel drug treatments><novel drugs><novel pharmaco-therapeutic><novel pharmacological therapeutic><novel strategies><novel strategy><novel therapeutic approach><novel therapeutic intervention><novel therapeutic strategies><novel therapeutics><novel therapy><novel therapy approach><ob/ob mouse><obesity intervention><obesity therapy><obesity treatment><oxidation><perilipin><pharmacologic><prevent><preventing><programs><rational design><respiratory mechanism><response><social role><synergism><type 2 DM><type II DM><type two diabetes><uptake><weight control><weight management><weights><white adipose tissue><wt-loss><yellow adipose tissue>